» Articles » PMID: 35798837

The Global, Regional and National Burden of Stomach Cancer and Its Attributable Risk Factors from 1990 to 2019

Overview
Journal Sci Rep
Specialty Science
Date 2022 Jul 7
PMID 35798837
Authors
Affiliations
Soon will be listed here.
Abstract

We aimed to estimate the incidence, mortality, and disability-adjusted life-years (DALYs) of stomach cancer at the global, regional, and national levels. Stomach cancer resulted in 1.3 million (1.2-1.4 million) incident cases, 9.5 hundred thousand (8.7-10.4 hundred thousand) deaths, and 22.2 million (20.3-24.1 million) DALYs in 2019. The age-standardized incidence rate, death rate and DALY rate were 15.6 (14.1-17.2), 11.9 (10.8-12.8), and 268.4 (245.5-290.6) per 100,000 person-years, respectively. Between 1990 and 2019, the global age-standardized incidence rate, death rate, and DALY rate decreased by - 30.5% (- 36.7 to - 22.9), - 41.9% (- 47.2 to - 36.3), and - 45.6% (- 50.8 to - 39.8), respectively. In 2019, most of the global numbers of incidence, death and DALYs were higher among males than females. A considerable burden of stomach cancer was attributable to smoking and a high-sodium diet. Although the global age-standardized incidence and death rates have decreased, continued growth in absolute numbers in some regions, especially in East Asia, poses a major global public health challenge. To address this, public health responses should be tailored to fit each country's unique situation. Primary and secondary prevention strategies with increased effectiveness are required to reduce the incidence and mortality of stomach cancer, particularly in populations with a high disease burden.

Citing Articles

Epidemiology and socioeconomic correlates of gastric cancer in Asia: results from the GLOBOCAN 2020 data and projections from 2020 to 2040.

Mousavi S, Ilaghi M, Elahi Vahed I, Nejadghaderi S Sci Rep. 2025; 15(1):6529.

PMID: 39988724 PMC: 11847935. DOI: 10.1038/s41598-025-90064-6.


The Role of TP53, KRAS, CDH1, Demographic and Clinical Variables in Gastric Cancer.

Siyam A, Ababneh S, Al-Odat I, Ababneh S, Alkhatib A Mater Sociomed. 2025; 36(4):280-287.

PMID: 39963439 PMC: 11830230. DOI: 10.5455/msm.2024.36.280-287.


The Role of Neural Network Analysis in Identifying Predictors of Gastric Cancer.

Siyam A Acta Inform Med. 2025; 32(2):99-106.

PMID: 39959676 PMC: 11821569. DOI: 10.5455/aim.2024.32.99-106.


Patients' experiences in early satiety after total gastrectomy for gastric cancer: a phenomenological study.

Vaccaro S, Diaz Crescitelli M, Mastrangelo S, Fornaciari N, Reverberi E, Di Leo S Front Nutr. 2025; 11():1511113.

PMID: 39830062 PMC: 11738932. DOI: 10.3389/fnut.2024.1511113.


Global, regional, and national trends in gastric cancer burden: 1990-2021 and projections to 2040.

Zhang T, Zhang Y, Leng X Front Oncol. 2024; 14:1468488.

PMID: 39726708 PMC: 11669584. DOI: 10.3389/fonc.2024.1468488.


References
1.
. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2019; 5(1):42-54. PMC: 7033564. DOI: 10.1016/S2468-1253(19)30328-0. View

2.
Areia M, Carvalho R, Cadime A, Goncalves F, Dinis-Ribeiro M . Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013; 18(5):325-37. DOI: 10.1111/hel.12050. View

3.
Li T, Hsieh J, Lee K, Hou M, Wu C, Kao H . Cost trend analysis of initial cancer treatment in Taiwan. PLoS One. 2014; 9(10):e108432. PMC: 4184791. DOI: 10.1371/journal.pone.0108432. View

4.
. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019; 19(1):1-48. PMC: 6441770. DOI: 10.5230/jgc.2019.19.e8. View

5.
Malfertheiner P, Megraud F, OMorain C, Gisbert J, Kuipers E, Axon A . Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016; 66(1):6-30. DOI: 10.1136/gutjnl-2016-312288. View